Relationship between tumorigenesis, metastasis, immune evasion, and chemoresistance in osteosarcoma therapy
Yan Yik Lim1, Ahmad Mujahid Ahmad Zaidi1, Mainul Haque2, Azizi Miskon3
1Faculty of Defence Science and Technology, National Defence University of Malaysia, Kuala Lumpur, Malaysia.
2Faculty of Medicine and Defence Health, National Defence University of Malaysia, Kuala Lumpur, Malaysia.
3Faculty of Engineering, National Defence University of Malaysia, Kuala Lumpur, Malaysia.
Open Access
Published: Aug 15, 2023
DOI: 10.7324/JAPS.2023.149907There has been no significant efficacy in treating osteosarcoma (OS) metastasis after nearly four decades of trials. This motivates us to elucidate OS therapies using their four bidirectional mutation stages. The historical developments and clinical advancements are briefly described to refresh the OS therapy status quo. However, the main issue of metastasis remains unresolved, accounting for 90% of pulmonary metastasis deaths. Thus, this metastasis problem is related to immune evasion and chemoresistance induced after long-term treatment by immunotherapy for tumorigenesis. Therefore, it is rational to discuss the relationship cycles of mutation stages, including tumorigenesis, metastasis, immune evasion, and chemoresistance. Even though many combinational and targeted therapies have been developed to intensify these mutation treatments, successful clinical translations with higher cure rates are still rare. Through this review, an in-depth understanding of the bidirectional relationship between the four OS mutation stages and their respective therapies is provided. Herein, we summarise the medicines for treating tumorigenesis, including Collagen beta (1-O) galactosyl transferase 2 inhibitors, transformer 2β, and ArfGAP with GTPase domain 1, miR-148a and miR-21-5p extracellular vesicles, and the long non-coding RNA leukemia inhibitory factor receptor antisense RNA1. Following the medicines for treating metastasis are AXL receptor tyrosine kinase, miR-135a-5p, messenger RNA B-cell lymphoma-6, transforming growth factor beta 1, T-cell immunoglobulin, and mucin-domain containing protein-3, suppressor of cytokine signalling-5, cancer susceptibility 15, Krüppel-like factor 3 antisense RNA 1, programmed cell death 4, autophagy-related gene 5, and Rab22a-NeoF1. Then the medicines for treating immune evasion are N-cadherin, ubiquitin-specific peptidase 12 inhibitors, latency-associated peptide domain inhibitors, anti-Wnt2 mAb, anti-αvβ8 integrin, hexokinase-2-mediated i-kappa-b-alpha, indoleamine 2,3-dioxygenase inhibitor with NO, and TGF-βRII with anti-IgG1. Finally, the medicines for treating chemoresistance are Dihydrofolate reductase, folylpoly-γ-glutamate synthetase, heat shock protein-90AA1, XCT-790, anlotinib tyrosine kinase inhibitor, and insulin-like growth factors 1. As a result, this contribution is expected to serve as a reference and guide for scientists and clinicians.
Lim YY, Zaidi AMA, Haque M, Miskon A. Relationship between tumorigenesis, metastasis, immune evasion, and chemoresistance in osteosarcoma therapy. J Appl Pharm Sci. 2023. http://doi.org/10.7324/JAPS.2023.149907
1. Moukengue B, Lallier M, Marchandet L, Baud’huin M, Verrecchia F, Ory B, et al. Origin and therapies of osteosarcoma. Cancers (Basel). 2022;14:3503. doi: https://doi.org/10.3390/cancers14143503
2. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50. doi: https://doi.org/10.1016/j.ejca.2018.11.027
3. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the automated childhood cancer information system project. Eur J Cancer. 2006;42:2124–35. doi: https://doi.org/10.1016/j.ejca.2006.05.015
4. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229–34. doi: https://doi.org/10.1002/ijc.24320
5. SEER. Surveillance, Epidemiology, and End Results (SEER) Program, incidence sub (1975–2017). SEER*Stat Database n.d.:9 [cited 2023 Jan 24] Registries. Available from: https://seer.cancer.gov/
6. Tsukamoto S, Errani C, Angelini A, Mavrogenis AF. Current treatment considerations for osteosarcoma metastatic at presentation. Orthopedics. 2020;43:e345–58. doi: https://doi.org/10.3928/01477447-20200721-05
7. Singh R, Valluri A, Didwania P, Lehrer EJ, Baliga S, Hiniker S, et al. Efficacy and safety of stereotactic body radiation therapy (SBRT) for pediatric malignancies: the LITE-SABR systematic review and meta-analysis. Adv Radiat Oncol. 2023;8:101123. doi: https://doi.org/10.1016/j.adro.2022.101123
8. Ahmed G, Zamzam M, Kamel A, Ahmed S, Salama A, Zaki I, et al. Effect of timing of pulmonary metastasis occurrence on the outcome of metastasectomy in osteosarcoma patients. J Pediatr Surg. 2019;54:775–9. doi: https://doi.org/10.1016/j.jpedsurg.2018.06.019
9. Silva JAM, Marchiori E, Macedo FCD, Silva PRGD, Amorim VB. Pulmonary metastasis of osteosarcoma: multiple presentations in a single patient. J Bras Pneumol. 2022;48:e20210478. doi: https://doi.org/10.36416/1806-3756/e20210478
10. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21:vii320–5. doi: https://doi.org/10.1093/annonc/mdq276
11. American Cancer Society. Survival rates for osteosarcoma. 2022 [cited 2023 Jan 28]. Available from: https://www.cancer.org/cancer/osteosarcoma/detection-diagnosis-staging/survival-rates.html
12. Tan G, Xu J, Yu Q, Yang Z, Zhang H. The safety and efficiency of photodynamic therapy for the treatment of osteosarcoma: a systematic review of in vitro experiment and animal model reports. Photodiagnosis Photodyn Ther. 2022;40:103093. doi: https://doi.org/10.1016/j.pdpdt.2022.103093
13. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, et al. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014;20:4200–9. doi: https://doi.org/10.1158/1078-0432.CCR-13-2574
14. Ni M. [Update and interpretation of 2021 National Comprehensive Cancer Network (NCCN) “Clinical Practice Guidelines for Bone Tumors”]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2021;35:1186–91. doi: https://doi.org/10.7507/1002-1892.202103073
15. Hattinger CM, Salaroglio IC, Fantoni L, Godel M, Casotti C, Kopecka J, et al. Strategies to overcome resistance to immune-based therapies in osteosarcoma. Int J Mol Sci. 2023;24:799. doi: https://doi.org/10.3390/ijms24010799
16. Evdokimova V, Gassmann H, Radvanyi L, Burdach SEG. Current state of immunotherapy and mechanisms of immune evasion in ewing sarcoma and osteosarcoma. Cancers (Basel). 2022;15:272. doi: https://doi.org/10.3390/cancers15010272
17. Li E, Zhong S, Ma G, Wang Q, Gao Y. MIR503HG overexpression inhibits the malignant behaviors of osteosarcoma cells by sponging miR-103a-3p. Crit Rev Eukaryot Gene Expr. 2022:33(3):1–11. doi: https://doi.org/10.1615/CritRevEukaryotGeneExpr.2022042373
18. Clapp B, Portela R, Sharma I, Nakanishi H, Marrero K, Schauer P, et al. Risk of non-hormonal cancer after bariatric surgery: meta-analysis of retrospective observational studies. Br J Surg. 2022;110:24–33. doi: https://doi.org/10.1093/bjs/znac343
19. Yeo SY, Bratke G, Grüll H. High intensity focused ultrasound for treatment of bone malignancies—20 years of history. Cancers (Basel). 2022;15:108. doi: https://doi.org/10.3390/cancers15010108
20. Guo S, Zhu X, Huang Z, Wei C, Yu J, Zhang L, et al. Genomic instability drives tumorigenesis and metastasis and its implications for cancer therapy. Biomed Pharmacother. 2023;157:114036. doi: https://doi.org/10.1016/j.biopha.2022.114036
21. Fazaeli H, Sheikholeslami A, Ghasemian F, Amini E, Sheykhhasan M. The emerging role of LncRNA FENDRR in multiple cancer: a review study. Curr Mol Med. 2022;22:606–29. doi: https://doi.org/10.2174/1566524022666220509122505
22. Shahpouri M, Adili-Aghdam MA, Mahmudi H, Jaymand M, Amoozgar Z, Akbari M, et al. Prospects for hypoxia-based drug delivery platforms for the elimination of advanced metastatic tumors: from 3D modeling to clinical concepts. J Control Release. 2023;353:1002–22. doi: https://doi.org/10.1016/j.jconrel.2022.12.009
23. Zheng Y, Chang X, Huang Y, He D. The application of antidepressant drugs in cancer treatment. Biomed Pharmacother. 2023;157:113985. doi: https://doi.org/10.1016/j.biopha.2022.11398524. López-Otín C, Pietrocola F, Roiz-Valle D, Galluzzi L, Kroemer G. Meta-hallmarks of aging and cancer. Cell Metab. 2023;35:12–35. doi: https://doi.org/10.1016/j.cmet.2022.11.001
25. Khadembaschi D, Jafri M, Praveen P, Parmar S, Breik O. Does neoadjuvant chemotherapy provide a survival benefit in maxillofacial osteosarcoma: a systematic review and pooled analysis. Oral Oncol. 2022;135:106133. doi: https://doi.org/10.1016/j.oraloncology.2022.106133
26. Lim YY, Miskon A, Zaidi AMA, Megat Ahmad MMH, Abu Bakar M. Numerical simulation study on relationship between the fracture mechanisms and residual membrane stresses of metallic material. J Funct Biomater. 2022c;13:20. doi: https://doi.org/10.3390/jfb13010020
27. Lim YY, Miskon A, Zaidi AMA. CuZn complex used in electrical biosensors for drug delivery systems. Materials (Basel). 2022a;15:7672. doi: https://doi.org/10.3390/ma15217672
28. Lim YY, Miskon A, Zaidi AMA, Megat Ahmad MMH, Abu Bakar M. Structural characterization analyses of low brass filler biomaterial for hard tissue implanted scaffold applications. Materials (Basel). 2022d;15:1421. doi: https://doi.org/10.3390/ma15041421
29. Lim YY, Miskon A, Zaidi AMA. Structural strength analyses for low brass filler biomaterial with anti-trauma effects in articular cartilage scaffold design. Materials (Basel). 2022b;15:4446. doi: https://doi.org/10.3390/ma15134446
30. Fierro Pineda JC, Wedekind MF, Glod JW. Immunotherapy approaches for rare pediatric solid tumors: advances and future directions. Curr Opin Pediatr. 2023;35:63–74. doi: https://doi.org/10.1097/MOP.0000000000001206
31. Ke CH, Chiu YH, Huang KC, Lin CS. Exposure of immunogenic tumor antigens in surrendered immunity and the significance of autologous tumor cell-based vaccination in precision medicine. Int J Mol Sci. 2022;24:147. doi: https://doi.org/10.3390/ijms24010147
32. Lim YY, Zaidi AMA, Miskon A. Composing on-program triggers and on-demand stimuli into biosensor drug carriers in drug delivery systems for programmable arthritis therapy. Pharmaceuticals. 2022e;15:1330. doi: https://doi.org/10.3390/ph15111330
33. Evans HM, Long JA. Characteristic effects upon growth, oestrus and ovulation induced by the intraperitoneal administration of fresh anterior hypophyseal substance. Proc Natl Acad Sci. 1922;8:38–9. doi: https://doi.org/10.1073/pnas.8.3.38
34. Li CH, Liu WK. Human pituitary growth hormone. Experientia. 1964;20:169–78. doi: https://doi.org/10.1007/BF02135393
35. Jaffe N, Frei E, Watts H, Traggis D. High-dose methotrexate in osteogenic sarcoma: a 5-year experience. Cancer Treat Rep. 1978;62:259–64.
36. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–30. doi: https://doi.org/10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E
37. Zapf J, Schmid CH, Froesch ER. 1 Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin Endocrinol Metab. 1984;13:3–30. doi: https://doi.org/10.1016/S0300-595X(84)80006-7
38. Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA, Heeley JD. Interleukin-1β is a potent inhibitor of bone formation in vitro. J Bone Miner Res. 2009;2:559–65. doi: https://doi.org/10.1002/jbmr.5650020612
39. Bengtsson BA, Edén S, Lönn L, Kvist H, Stokland A, Lindstedt G, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993;76:309–17. doi: https://doi.org/10.1210/jcem.76.2.8432773
40. Gentet JC, Brunat-Mentigny M, Demaille MC, Pein F, Avet-Loiseau H, Berger C, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the french society of paediatriconcology. Eur J Cancer. 1997;33:232–7. doi: https://doi.org/10.1016/S0959-8049(96)00439-X
41. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res. 2002;8:3584–91.
42. Nardin A, Lefebvre M, Labroquere K, Faure O, Abastado J. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets. 2006;6:123–33. doi: https://doi.org/10.2174/156800906776056473
43. Tang QL, Zhao ZQ, Li J, Liang Y, Yin JQ, Zou CY, et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011;311:113–21. doi: https://doi.org/10.1016/j.canlet.2011.07.016
44. Gordon EM, Chua-Alcala VS, Kim K, Baby R, Angel N, Quon D, et al. A phase I/II investigation of nivolumab and ABI-009 (nab -sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma: preliminary efficacy and safety results. J Clin Oncol. 2019;37:11057. doi: https://doi.org/10.1200/JCO.2019.37.15_suppl.11057
45. Manji A, Samson Y, Deyell RJ, Johnston DL, Lewis VA, Zorzi AP, et al. Low-dose metronomic topotecan and pazopanib (TOPAZ) in children with relapsed or refractory solid tumors: a C17 Canadian phase I clinical trial. Cancers (Basel). 2022;14:2985. doi: https://doi.org/10.3390/cancers14122985
46. Gartrell J, Panetta JC, Baker SD, Chen YL, Hawkins DS, Ostrenga A, et al. The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from children’s oncology group and NRG oncology study ARST1321. Cancer Chemother Pharmacol. 2022;89:551–7. doi: https://doi.org/10.1007/s00280-022-04397-4
47. Szkandera J. Keeping up the ‘race pace’ in a patient with nonuterine leiomyosarcoma. Futur Oncol. 2022;18:12–6. doi: https://doi.org/10.2217/fon-2022-0636
48. Liu Z, Wang X, Wang J, Zhang P, Li C, Wang B, et al. Gemcitabine plus anlotinib is effective and safe compared to gemcitabine plus docetaxel in advanced soft tissue sarcoma. Front Oncol. 2022;12:922127. doi: https://doi.org/10.3389/fonc.2022.922127
49. Villaruz LC, Kelly K, Waqar SN, Davis EJ, Shapiro G, LoRusso P, et al. NCI 9938: phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors. J Clin Oncol. 2022;40:3012. doi: https://doi.org/10.1200/JCO.2022.40.16_suppl.3012
50. Plummer R, Dean E, Arkenau HT, Redfern C, Spira AI, Melear JM, et al. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer. 2022;163:19–26. doi: https://doi.org/10.1016/j.lungcan.2021.11.011
51. Brahmi M, Gautier J, Dufresne A, Marec-Berard P, Cropet C, Vizoso S, et al. REGOMAIN: a randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete. J Clin Oncol. 2022;40:TPS11585. doi: https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS11585
52. Vienot A, Vernerey D, Bouard A, Klajer E, Asgarov K, Kim S, et al. SO-20 stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: an exploratory analysis of the CORRECT trial. Ann Oncol. 2022;33:S365. doi: https://doi.org/10.1016/j.annonc.2022.04.419
53. Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, et al. [89Zr]ZrDFO-CR011 PET correlates with response to glycoprotein nonmetastatic melanoma B–targeted therapy in triple-negative breast cancer. Mol Cancer Ther. 2022;21:440–7. doi: https://doi.org/10.1158/1535-7163.MCT-21-059054. Lazaratos AM, Annis MG, Siegel PM. GPNMB: a potent inducer of immunosuppression in cancer. Oncogene. 2022;41:4573–90. doi: https://doi.org/10.1038/s41388-022-02443-2
55. Albarrán V, Villamayor ML, Chamorro J, Rosero DI, Pozas J, San Román M, et al. Receptor tyrosine kinase inhibitors for the treatment of recurrent and unresectable bone sarcomas. Int J Mol Sci. 2022;23:13784. doi: https://doi.org/10.3390/ijms232213784
56. Pearson AD, Gaspar N, Janeway K, Campbell-Hewson Q, Lawlor ER, Copland C, et al. Paediatric strategy forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. Eur J Cancer. 2022;173:71–90. doi: https://doi.org/10.1016/j.ejca.2022.06.008
57. Teo MYM, Fong JY, Lim WM, In LLA. Current advances and trends in KRAS targeted therapies for colorectal cancer. Mol Cancer Res. 2022;20:30–44. doi: https://doi.org/10.1158/1541-7786.MCR-21-0248
58. Al Shihabi A, Davarifar A, Nguyen HTL, Tavanaie N, Nelson SD, Yanagawa J, et al. Personalized chordoma organoids for drug discovery studies. Sci Adv. 2022;8:3674. doi: https://doi.org/10.1126/sciadv.abl3674
59. Cash T, Jonus HC, Tsvetkova M, Beumer JH, Lee JY, Henry C, et al. A phase I study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors. J Clin Oncol. 2020;38:10541. doi: https://doi.org/10.1200/JCO.2020.38.15_suppl.10541
60. Duarte JA, de Barros ALB, Leite EA. The potential use of simvastatin for cancer treatment: a review. Biomed Pharmacother. 2021;141:111858. doi: https://doi.org/10.1016/j.biopha.2021.111858
61. Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, et al. Osteosarcoma. Nat Rev Dis Prim. 2022;8:77. doi: https://doi.org/10.1038/s41572-022-00409-y
62. Pascual-Pasto G, Castillo-Ecija H, Unceta N, Aschero R, Resa-Pares C, Gómez-Caballero A, et al. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. J Control Release. 2022;342:81–92. doi: https://doi.org/10.1016/j.jconrel.2021.12.035
63. Digklia A, Kollar A, Kronig MN, Britschgi C, Rordorf T, Joerger M, et al. 1495P SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): final results from the phase Ib/II trial with >2y median follow up. Ann Oncol. 2022;33:S1230. doi: https://doi.org/10.1016/j.annonc.2022.07.1598
64. Omar S, Albritton K, Heym K, Wang J, Ray A. Multimodal treatment of sarcomas linked to BCOR-CCNB3 fusion in pediatrics: a 3-patient case series. Clin Pediatr Hematol. 2022;29:60–4. doi: https://doi.org/10.15264/cpho.2022.29.2.60
65. Smida M, Ammar A, Fedhila F, Douira W, Sassi S. Periosteal preservation: a new technique in resection of bone high-grade malignant tumors in children—about eleven cases. World J Surg Oncol. 2022;20:312. doi: https://doi.org/10.1186/s12957-022-02749-1
66. Puppo M, Jaafar M, Diaz JJ, Marcel V, Clézardin P. MiRNAs and snoRNAs in bone metastasis: functional roles and clinical potential. Cancers (Basel). 2022;15:242. doi: https://doi.org/10.3390/cancers15010242
67. Sadeh M, Toledano H, Cohen IJ. A comprehensive review of neuropsychologic studies supports the concept that adequate folinic acid rescue prevents post methotrexate neurotoxicity. J Pediatr Hematol Oncol. 2023;45:1–11. doi: https://doi.org/10.1097/MPH.0000000000002604
68. Hainaut P, Pfeifer GP. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb Perspect Med. 2016;6:a026179. doi: https://doi.org/10.1101/cshperspect.a026179
69. Li VD, Li KH, Li JT. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from the cancer genome atlas and the international agency for research on cancer TP53 database. J Cancer Res Clin Oncol. 2019;145:625–36. doi: https://doi.org/10.1007/s00432-018-2817-z70. Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37:865–76. doi: https://doi.org/10.1002/humu.23035
71. Synoradzki KJ, Bartnik E, Czarnecka AM, Fiedorowicz M, Firlej W, Brodziak A, et al. TP53 in biology and treatment of osteosarcoma. Cancers (Basel). 2021;13:4284. doi: https://doi.org/10.3390/cancers13174284
72. Lim YY, Zaidi AMA, Miskon A. Combining copper and zinc into a biosensor for anti-chemoresistance and achieving osteosarcoma therapeutic efficacy. Molecules. 2023;28:2920. doi: https://doi.org/10.3390/molecules28072920
73. Li S, Wang X. The potential roles of exosomal noncoding RNAs in osteosarcoma. J Cell Physiol. 2021;236:3354–65. doi: https://doi.org/10.1002/jcp.30101
74. Abhange K, Makler A, Wen Y, Ramnauth N, Mao W, Asghar W, et al. Small extracellular vesicles in cancer. Bioact Mater. 2021;6:3705–43. doi: https://doi.org/10.1016/j.bioactmat.2021.03.015
75. Kluszczynska K, Czyz M. Extracellular vesicles-based cell-cell communication in melanoma: new perspectives in diagnostics and therapy. Int J Mol Sci. 2023;24:965. doi: https://doi.org/10.3390/ijms24020965
76. Song H, Zhao J, Cheng J, Feng Z, Wang J, Momtazi-Borojeni AA, et al. Extracellular vesicles in chondrogenesis and Cartilage regeneration. J Cell Mol Med. 2021;25:4883–92. doi: https://doi.org/10.1111/jcmm.16290
77. Jothimani G, Pathak S, Dutta S, Duttaroy AK, Banerjee A. A comprehensive cancer-associated microRNA expression profiling and proteomic analysis of human umbilical cord mesenchymal stem cell-derived exosomes. Tissue Eng Regen Med. 2022;19:1013–31. doi: https://doi.org/10.1007/s13770-022-00450-8
78. Kwok ZH, Wang C, Jin Y. Extracellular vesicle transportation and uptake by recipient cells: a critical process to regulate human diseases. Processes. 2021;9:273. doi: https://doi.org/10.3390/pr9020273
79. Ross J, McIver Z, Lambert T, Piergentili C, Bird JE, Gallagher KJ, et al. Pore dynamics and asymmetric cargo loading in an encapsulin nanocompartment. Sci Adv. 2022;8:4461. doi: https://doi.org/10.1126/sciadv.abj4461
80. van Niel G, Carter DRF, Clayton A, Lambert DW, Raposo G, Vader P. Challenges and directions in studying cell–cell communication by extracellular vesicles. Nat Rev Mol Cell Biol. 2022;23:369–82. doi: https://doi.org/10.1038/s41580-022-00460-3
81. Xiang Y, Hu C, Wu G, Xu S, Li Y. Nanomaterial-based microfluidic systems for cancer biomarker detection: recent applications and future perspectives. TrAC Trends Anal Chem. 2023;158:116835. doi: https://doi.org/10.1016/j.trac.2022.116835
82. Liang Y, Fang D, Gao X, Deng X, Chen N, Wu J, et al. Circulating microRNAs as emerging regulators of COVID-19. Theranostics. 2023;13:125–47. doi: https://doi.org/10.7150/thno.78164
83. Laviron M, Boissonnas A. Ontogeny of tumor-associated macrophages. Front Immunol. 2019;10:1799. doi: https://doi.org/10.3389/fimmu.2019.01799
84. Wei Z, Zheng D, Pi W, Qiu Y, Xia K, Guo W. Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway. J Bone Oncol. 2023;38:100468. doi: https://doi.org/10.1016/j.jbo.2023.100468
85. Lu D, Liu R, Zhou Y, Zhang Z, Jiang X, Xu J, et al. FOXO3a-dependent up-regulation of HSP90 alleviates cisplatin-induced apoptosis by activating FUNDC1-mediated mitophagy in hypoxic osteosarcoma cells. Cell Signal. 2023;101:110500. doi: https://doi.org/10.1016/j.cellsig.2022.110500
86. Raimondi L, De Luca A, Gallo A, Costa V, Russelli G, Cuscino N, et al. Osteosarcoma cell-derived exosomes affect tumor microenvironment by specific packaging of microRNAs. Carcinogenesis. 2020;41:666–77. doi: https://doi.org/10.1093/carcin/bgz13087. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369–82. doi: https://doi.org/10.1038/s41577-019-0127-6
88. Wolf-Dennen K, Gordon N, Kleinerman ES. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology. 2020;9:1747677. doi: https://doi.org/10.1080/2162402X.2020.1747677
89. Lopes N, Vivier E, Narni-Mancinelli E. Natural killer cells and type 1 innate lymphoid cells in cancer. Semin Immunol. 2023;66:101709. doi: https://doi.org/10.1016/j.smim.2022.101709
90. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11:1008. doi: https://doi.org/10.1038/s41467-020-14646-w
91. Verma A, Mathur R, Farooque A, Kaul V, Gupta S, Dwarakanath BS. T-Regulatory cells in tumor progression and therapy. Cancer Manag Res. 2019;11:10731–47. doi: https://doi.org/10.2147/CMAR.S228887
92. Ray SK, Mukherjee S. Altering landscape of cancer vaccines: unique platforms, research on therapeutic applications and recent patents. Recent Pat Anticancer Drug Discov. 2023;18:133–46. doi: https://doi.org/10.2174/1574892817666220414110335
93. Bayatipoor H, Mehdizadeh S, Jafarpour R, Shojaei Z, Pashangzadeh S, Motallebnezhad M. Role of NKT cells in cancer immunotherapy—from bench to bed. Med Oncol. 2022;40:29. doi: https://doi.org/10.1007/s12032-022-01888-5
94. Metelli A, Wu BX, Riesenberg B, Guglietta S, Huck JD, Mills C, et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β. Sci Transl Med. 2020;12:4860. doi: https://doi.org/10.1126/scitranslmed.aay4860
95. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–43. doi: https://doi.org/10.1038/nature25492
96. Shima T, Shimoda M, Shigenobu T, Ohtsuka T, Nishimura T, Emoto K, et al. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma. Cancer Sci. 2020;111:727–38. doi: https://doi.org/10.1111/cas.14272
97. Wang X, Chen Z, Li B, Fan J, Xu W, Xiao J. Immunotherapy as a promising option for the treatment of advanced chordoma: a systemic review. Cancers (Basel). 2022;15:264. doi: https://doi.org/10.3390/cancers15010264
98. Huang T, Tan X, Huang H, Li YT, Liu BL, Liu KS, et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 2022;71:333–44.
99. Yue P, Han B, Zhao Y. Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches. Mol Omi. 2023;19:297–307. doi: https://doi.org/10.1039/D2MO00220E
100. Fan L, Qu Y, Tong W, Lin H, Xiao B. Application value of a selenium-hydroxyapatite nanodelivery system as osteosarcoma treatment. Mater Express. 2022;12:1033–41. doi: https://doi.org/10.1166/mex.2022.2256
101. Garcia-Ortega DY, Cabrera-Nieto SA, Caro-Sánchez HS, Cruz-Ramos M. An overview of resistance to chemotherapy in osteosarcoma and future perspectives. Cancer Drug Resist. 2022;5:762–93. doi: https://doi.org/10.20517/cdr.2022.18
102. Inui T, Nomoto R, Yokota J, Yamashita T, Okada K, Kishimoto W, et al. Establishment of MDR1-knockout human enteroids for pharmaceutical application. Drug Metab Pharmacokinet. 2023;48:100476. doi: https://doi.org/10.1016/j.dmpk.2022.100476
103. Cai JX, Liu JH, Wu JY, Li YJ, Qiu XH, Xu WJ, et al. Hybrid cell membrane-functionalized biomimetic nanoparticles for targeted therapy of osteosarcoma. Int J Nanomed. 2022;17:837–54. doi: https://doi.org/10.2147/IJN.S346685
104. Zhang XB, Zhang RH, Su X, Qi J, Hu YC, Shi JT, et al. Exosomes in osteosarcoma research and preclinical practice. Am J Transl Res. 2021;13:882–97. 105. Weinman MA, Ramsey SA, Leeper HJ, Brady JV, Schlueter A, Stanisheuski S, et al. Exosomal proteomic signatures correlate with drug resistance and carboplatin treatment outcome in a spontaneous model of canine osteosarcoma. Cancer Cell Int. 2021;21:245. doi: https://doi.org/10.1186/s12935-021-01943-7
106. Homayoonfal M, Asemi Z, Yousefi B. Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis. Cell Mol Biol Lett. 2022;27:21. doi: https://doi.org/10.1186/s11658-022-00320-0
107. Cheng B, Yu Q, Wang W. Intimate communications within the tumor microenvironment: stromal factors function as an orchestra. J Biomed Sci. 2023;30:1. doi: https://doi.org/10.1186/s12929-022-00894-z
108. Chaudhary A, Raza SS, Haque R. Transcriptional factors targeting in cancer stem cells for tumor modulation. Semin Cancer Biol. 2023;88:123–37. doi: https://doi.org/10.1016/j.semcancer.2022.12.010
109. Wu T, Yang W, Sun A, Wei Z, Lin Q. The role of CXC chemokines in cancer progression. Cancers (Basel). 2022;15:167. doi: https://doi.org/10.3390/cancers15010167
110. Wang Y, Chu Y, Li K, Zhang G, Guo Z, Wu X, et al. Exosomes secreted by adipose-derived mesenchymal stem cells foster metastasis and osteosarcoma proliferation by increasing COLGALT2 expression. Front Cell Dev Biol. 2020;8:353. doi: https://doi.org/10.3389/fcell.2020.00353
111. Marulanda J, Tauer JT, Boraschi-Diaz I, Bardai G, Rauch F. Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta. Sci Rep. 2023;13:5010. doi: https://doi.org/10.1038/s41598-023-32221-3
112. Zhang H, Wang J, Ren T, Huang Y, Liang X, Yu Y, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B. Cancer Lett. 2020a;490:54–65. doi: https://doi.org/10.1016/j.canlet.2020.07.008
113. Tian B, Du X, Zheng S, Zhang Y. The role of tumor microenvironment in regulating the plasticity of osteosarcoma cells. Int J Mol Sci. 2022;23:16155. doi: https://doi.org/10.3390/ijms232416155
114. Han F, Pu P, Wang C, Ding X, Zhu Z, Xiang W, et al. Osteosarcoma cell-derived exosomal miR-1307 promotes tumorgenesis via targeting AGAP1. Biomed Res Int. 2021;2021:1–17. doi: https://doi.org/10.1155/2021/7358153
115. Tan L, Wang Y, Hu X, Min L. The roles of exosomes in metastasis of sarcoma: from biomarkers to therapeutic targets. Biomolecules. 2023;13:456. doi: https://doi.org/10.3390/biom13030456
116. Shiau JP, Chuang YT, Yen CY, Chang FR, Yang KH, Hou MF, et al. Modulation of AKT pathway-targeting miRNAs for cancer cell treatment with natural products. Int J Mol Sci. 2023;24:3688. doi: https://doi.org/10.3390/ijms24043688
117. Zhang H, Yu Y, Wang J, Han Y, Ren T, Huang Y, et al. Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis. Cancer Cell Int. 2021;21:192. doi: https://doi.org/10.1186/s12935-021-01893-0
118. Alfieri M, Meo L, Ragno P. Posttranscriptional regulation of the plasminogen activation system by non-coding RNA in cancer. Int J Mol Sci. 2023;24:962. doi: https://doi.org/10.3390/ijms24020962
119. Luo X, Li Y, Hua Z, Xue X, Wang X, Pang M, et al. Exosomes-mediated tumor metastasis through reshaping tumor microenvironment and distant niche. J Control Release. 2023;353:327–36. doi: https://doi.org/10.1016/j.jconrel.2022.11.050
120. Zhang W, Yan Y, Peng J, Thakur A, Bai N, Yang K, et al. Decoding roles of exosomal lncRNAs in tumor-immune regulation and therapeutic potential. Cancers (Basel). 2022;15:286. doi: https://doi.org/10.3390/cancers15010286
121. Li Q, Wang X, Jiang N, Xie X, Liu N, Liu J, et al. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma. Cancer Med. 2020;9:6354–66. doi: https://doi.org/10.1002/cam4.3303122. Zhang H, Du Y, Xin P, Man X. The LINC00852/miR-29a-3p/JARID2 axis regulates the proliferation and invasion of prostate cancer cell. BMC Cancer. 2022;22:1269. doi: https://doi.org/10.1186/s12885-022-10263-6
123. Ge X, Liu WW, Zhao W, Feng S, Duan A, Ji C, et al. Exosomal transfer of LCP1 promotes osteosarcoma cell tumorigenesis and metastasis by activating the JAK2/STAT3 signaling pathway. Mol Ther Nucleic Acids. 2020;21:900–15. doi: https://doi.org/10.1016/j.omtn.2020.07.025
124. Zhang H, Song J, Zhou X. Long noncoding RNA P53 upregulated regulator of P53 levels promotes osteogenic differentiation in osteoporosis progression through sponging miR-135a-5p. J Biomater Tissue Eng. 2022;12:2085–91. doi: https://doi.org/10.1166/jbt.2022.3125
125. Zhang K, Dong C, Chen M, Yang T, Wang X, Gao Y, et al. Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma. Theranostics. 2020;10:411–25. doi: https://doi.org/10.7150/thno.33482
126. Mei X, Zhang B, Zhao M, Lu Q. An update on epigenetic regulation in autoimmune diseases. J Transl Autoimmun. 2022;5:100176. doi: https://doi.org/10.1016/j.jtauto.2022.100176
127. Mazumdar A, Urdinez J, Boro A, Migliavacca J, Arlt MJE, Muff R, et al. Osteosarcoma-derived extracellular vesicles induce lung fibroblast reprogramming. Int J Mol Sci. 2020;21:5451. doi: https://doi.org/10.3390/ijms21155451
128. Tripathi R, Sinha NR, Kempuraj D, Balne PK, Landreneau JR, Juneja A, et al. Evaluation of CRISPR/Cas9 mediated TGIF gene editing to inhibit corneal fibrosis in vitro. Exp Eye Res. 2022;220:109113. doi: https://doi.org/10.1016/j.exer.2022.109113
129. Cheng Z, Wang L, Wu C, Huang L, Ruan Y, Xue W. Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through tim-3. Arch Med Res. 2021;52:200–10. doi: https://doi.org/10.1016/j.arcmed.2020.10.018
130. Gomes de Morais AL, Cerdá S, de Miguel M. New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors. Curr Oncol Rep. 2022;24:651–8. doi: https://doi.org/10.1007/s11912-022-01218-y
131. Zhang Y, Liu Z, Yang X, Lu W, Chen Y, Lin Y, et al. H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts. Theranostics. 2021;11:1473–92. doi: https://doi.org/10.7150/thno.51245
132. Wang Y, Han Y, Wang L, Zou M, Sun Y, Sun H, et al. Mycoplasma gallisepticum escapes the host immune response via gga-miR-365-3p/SOCS5/STATs axis. Vet Res. 2022;53:103. doi: https://doi.org/10.1186/s13567-022-01117-x
133. Zhang H, Wang J, Ren T, Huang Y, Yu Y, Chen C, et al. LncRNA CASC15 is upregulated in osteosarcoma plasma exosomes and CASC15 knockdown inhibits osteosarcoma progression by regulating miR-338-3p/RAB14 axis. Onco Targets Ther. 2020b;13:12055–66. doi: https://doi.org/10.2147/OTT.S282053
134. Chen C, Liu L. Silencing of lncRNA KLF3-AS1 represses cell growth in osteosarcoma via miR-338-3p/MEF2C axis. J Clin Lab Anal. 2022;36:e24698. doi: https://doi.org/10.1002/jcla.24698
135. Qin F, Tang H, Zhang Y, Zhang Z, Huang P, Zhu J. Bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-208a promotes osteosarcoma cell proliferation, migration, and invasion. J Cell Physiol. 2020;235:4734–45. doi: https://doi.org/10.1002/jcp.29351
136. Wang Q, Zhou H, Zhu X, Jiang F, Yu Q, Zhang J, et al. miR-208 inhibits myocardial tissues apoptosis in mice with acute myocardial infarction by targeting inhibition of PDCD4. J Biochem Mol Toxicol. 2022;36:e23202. doi: https://doi.org/10.1002/jbt.23202
137. Huang Y, Liu W, He B, Wang L, Zhang F, Shu H, et al. Exosomes derived from bone marrow mesenchymal stem cells promote osteosarcoma development by activating oncogenic autophagy. J Bone Oncol. 2020;21:100280. doi: https://doi.org/10.1016/j.jbo.2020.100280
138. Yu Z, Tang H, Chen S, Xie Y, Shi L, Xia S, et al. Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy. Drug Resist Updat. 2022;67:100915. doi: https://doi.org/10.1016/j.drup.2022.100915
139. Zhong L, Liao D, Li J, Liu W, Wang J, Zeng C, et al. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. Signal Transduct Target Ther. 2021;6:59. doi: https://doi.org/10.1038/s41392-020-00414-1
140. Zeng C, Zhong L, Liu W, Zhang Y, Yu X, Wang X, et al. Targeting the lysosomal degradation of Rab22a-NeoF1 fusion protein for osteosarcoma lung metastasis. Adv Sci. 2022;10:2205483. doi: https://doi.org/10.1002/advs.202205483
141. Ye H, Hu X, Wen Y, Tu C, Hornicek F, Duan Z, et al. Exosomes in the tumor microenvironment of sarcoma: from biological functions to clinical applications. J Nanobiotechnol. 2022;20:403. doi: https://doi.org/10.1186/s12951-022-01609-0
142. Zhu T, Han J, Yang L, Cai Z, Sun W, Hua Y, et al. Immune microenvironment in osteosarcoma: components, therapeutic strategies and clinical applications. Front Immunol. 2022;13:907550. doi: https://doi.org/10.3389/fimmu.2022.907550
143. Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12:6273–90. doi: https://doi.org/10.7150/thno.76854
144. Wang J, Zhang H, Sun X, Wang X, Ren T, Huang Y, et al. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients. J Nanobiotechnol. 2020;18:151. doi: https://doi.org/10.1186/s12951-020-00710-6
145. Chang SLY, Lee CW, Yang CY, Lin ZC, Peng KT, Liu SC, et al. IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation. Biochem Pharmacol. 2023;210:115472. doi: https://doi.org/10.1016/j.bcp.2023.115472
146. Zhan X, He Q, Sheng J, Jiang X, Lin L, Huang Y, et al. USP12 positively regulates M-MDSC function to inhibit antitumour immunity through deubiquitinating and stabilizing p65. Immunology. 2022;167:544–57. doi: https://doi.org/10.1111/imm.13552
147. Zhang X, Jin X, Guan L, Lin X, Li X, Li Y. IgG4-Related disease with gastrointestinal involvement: case reports and literature review. Front Immunol. 2022;13. doi: https://doi.org/10.3389/fimmu.2022.816830
148. Chen Z, Yu H, Chen X, Chen W, Song W, Li Z. Mutual regulation between glycosylation and transforming growth factor-β isoforms signaling pathway. Int J Biol Macromol. 2023;236:123818. doi: https://doi.org/10.1016/j.ijbiomac.2023.123818
149. Chen SY, Mamai O, Akhurst RJ. TGFβ: signaling blockade for cancer immunotherapy. Annu Rev Cancer Biol. 2022;6:123–46. doi: https://doi.org/10.1146/annurev-cancerbio-070620-103554
150. Qin K, Yu M, Fan J, Wang H, Zhao P, Zhao G, et al. Canonical and noncanonical Wnt signaling: a comprehensive review of multilayered mediators, signaling mechanisms and crosstalk with major signaling pathways. Genes Dis. 2023. doi: https://doi.org/10.1016/j.gendis.2023.01.030
151. Duan Z, Lin X, Wang L, Zhen Q, Jiang Y, Chen C, et al. Specificity of TGF-β1 signal designated by LRRC33 and integrin αVβ8. Nat Commun. 2022;13:4988. doi: https://doi.org/10.1038/s41467-022-32655-9
152. Dodagatta-Marri E, Ma HY, Liang B, Li J, Meyer DS, Chen SY, et al. Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. Cell Rep. 2021;36:109309. doi: https://doi.org/10.1016/j.celrep.2021.109309
153. Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. Cell Metab. 2022;34:1312–24.e6. doi: https://doi.org/10.1016/j.cmet.2022.08.002154.
154. Zhang Y, Fu J, Liu S, Wang L, Qiu J, van Schaik EJ, et al. Coxiella burnetii inhibits host immunity by a protein phosphatase adapted from glycolysis. Proc Natl Acad Sci. 2022;119:e2110877119. doi: https://doi.org/10.1073/pnas.2110877119
155. Du L, He H, Xiao Z, Xiao H, An Y, Zhong H, et al. GSH-responsive metal–organic framework for intratumoral release of NO and IDO inhibitor to enhance antitumor immunotherapy. Small. 2022;18:2107732. doi: https://doi.org/10.1002/smll.202107732
156. Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022;110:102461. doi: https://doi.org/10.1016/j.ctrv.2022.102461
157. Gulley JL, Schlom J, Barcellos-Hoff MH, Wang X, Seoane J, Audhuy F, et al. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2022;16:2117–34. doi: https://doi.org/10.1002/1878-0261.13146
158. Metropulos AE, Munshi HG, Principe DR. The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial. EBioMedicine. 2022;86:104380. doi: https://doi.org/10.1016/j.ebiom.2022.104380
159. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39. doi: https://doi.org/10.1016/j.intimp.2018.06.001
160. Martin CJ, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, et al. Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci Transl Med. 2020;12:8456. doi: https://doi.org/10.1126/scitranslmed.aay8456
161. Chen C, Shi Q, Xu J, Ren T, Huang Y, Guo W. Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma. Cell Death Discov. 2022;8:488. doi: https://doi.org/10.1038/s41420-022-01252-6
162. Northcote-Smith J, Suntharalingam K. Targeting chemotherapy-resistant tumour sub-populations using inorganic chemistry: anti-cancer stem cell metal complexes. Curr Opin Chem Biol. 2023;72:102237. doi: https://doi.org/10.1016/j.cbpa.2022.102237
163. Costa AR, Duarte AC, Costa-Brito AR, Gonçalves I, Santos CRA. Bitter taste signaling in cancer. Life Sci. 2023;315:121363. doi: https://doi.org/10.1016/j.lfs.2022.121363
164. Aprile M, Costa V, Cimmino A, Calin GA. Emerging role of oncogenic long noncoding RNA as cancer biomarkers. Int J Cancer. 2023;152:822–34. doi: https://doi.org/10.1002/ijc.34282
165. Zhang Q, Liu N, Wang J, Liu Y, Wang K, Zhang J, et al. The recent advance of cell-penetrating and tumor-targeting peptides as drug delivery systems based on tumor microenvironment. Mol Pharm. 2023;20(2):789–809. doi: https://doi.org/10.1021/acs.molpharmaceut.2c00629
166. de Castro KC, Coco JC, dos Santos ÉM, Ataide JA, Martinez RM, do Nascimento MHM, et al. Pluronic® triblock copolymer-based nanoformulations for cancer therapy: a 10-year overview. J Control Release. 2023;353:802–22. doi: https://doi.org/10.1016/j.jconrel.2022.12.017
167. Wang H, Zhou X, Li C, Yan S, Feng C, He J, et al. The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy. J Hematol Oncol. 2022;15:140. doi: https://doi.org/10.1186/s13045-022-01365-6
168. Marques da Costa ME, Marchais A, Gomez-Brouchet A, Job B, Assoun N, Daudigeos-Dubus E, et al. In-vitro and in-vivo establishment and characterization of bioluminescent orthotopic chemotherapy-resistant human osteosarcoma models in NSG mice. Cancers (Basel). 2019;11:997. doi: https://doi.org/10.3390/cancers11070997
169. Salem IM, Mostafa SM, Salama I, El-Sabbagh OI, Hegazy WAH, Ibrahim TS. Design, synthesis and antitumor evaluation of novel pyrazolo[3,4- d ]pyrimidines incorporating different amino acidconjugates as potential DHFR inhibitors. J Enzyme Inhib Med Chem. 2023;38:203–15. doi: https://doi.org/10.1080/14756366.2022.2142786
170. Yu W, Min D, Lin F, Zheng S, Tang L, He A, et al. SKA1 induces de novo MTX-resistance in osteosarcoma through inhibiting FPGS transcription. FEBS J. 2019;286:2399–414. doi: https://doi.org/10.1111/febs.14808
171. Zhang Y, Zhang C, Man X, Men Y, Ren X, Li X, et al. Functional characterization of the SiFPGS2 gene of foxtail millet in folate accumulation and root development. Plant Growth Regul. 2022. doi: https://doi.org/10.1007/s10725-022-00904-y
172. Xiao X, Wang W, Li Y, Yang D, Li X, Shen C, et al. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res. 2018;37:201. doi: https://doi.org/10.1186/s13046-018-0880-6
173. Chen Y, Zhang K, Li Y, Guo R, Zhang K, Zhong G, et al. Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1. J Cell Mol Med. 2019;23:2115–24. doi: https://doi.org/10.1111/jcmm.14123
174. Wang G, Cao L, Jiang Y, Zhang T, Wang H, Wang Z, et al. Anlotinib reverses multidrug resistance (MDR) in osteosarcoma by inhibiting P-glycoprotein (PGP1) function in vitro and in vivo. Front Pharmacol. 2022;12:798837. doi: https://doi.org/10.3389/fphar.2021.798837
175. He Q, Hao P, He G, Mai H, Liu W, Zhang W, et al. IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells. J Transl Med. 2022;20:348. doi: https://doi.org/10.1186/s12967-022-03549-7
176. Nwabo Kamdje AH, Seke Etet PF, Kipanyula MJ, Vecchio L, Tagne Simo R, Njamnshi AK, et al. Insulin-like growth factor-1 signaling in the tumor microenvironment: carcinogenesis, cancer drug resistance, and therapeutic potential. Front Endocrinol (Lausanne). 2022;13:927390. doi: https://doi.org/10.3389/fendo.2022.927390
177. Celik B, Cicek K, Leal AF, Tomatsu S. Regulation of molecular targets in osteosarcoma treatment. Int J Mol Sci. 2022;23:12583. doi: https://doi.org/10.3390/ijms232012583
178. Li X, Liu YY, Zhang X, Shen J, Xu R, Liu YY, et al. Circular RNA hsa_circ_0000073 contributes to osteosarcoma cell proliferation, migration, invasion and methotrexate resistance by sponging miR-145-5p and miR-151-3p and upregulating NRAS. Aging (Albany NY). 2020;12:14157–73. doi: https://doi.org/10.18632/aging.103423
179. Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. Int J Mol Sci. 2020;21:6885. doi: https://doi.org/10.3390/ijms21186885
180. Wei W, Ji L, Duan W, Zhu J. Circular RNA circ_0081001 knockdown enhances methotrexate sensitivity in osteosarcoma cells by regulating miR-494-3p/TGM2 axis. J Orthop Surg Res. 2021;16:50. doi: https://doi.org/10.1186/s13018-020-02169-5
181. Liu S, Duan K, Zhang X, Cao X, Wang X, Meng F, et al. Circ_0081001 down-regulates miR-494-3p to enhance BACH1 expression and promotes osteosarcoma progression. Aging (Albany NY). 2021;13:17274–84. doi: https://doi.org/10.18632/aging.203207
182. Bai Y, Li Y, Bai J, Zhang Y. Hsa_circ_0004674 promotes osteosarcoma doxorubicin resistance by regulating the miR-342-3p/FBN1 axis. J Orthop Surg Res. 2021;16:510. doi: https://doi.org/10.1186/s13018-021-02631-y
183. Ma XL, Zhan TC, Hu JP, Zhang CL, Zhu KP. Doxorubicin-induced novel circRNA_0004674 facilitates osteosarcoma progression and chemoresistance by upregulating MCL1 through miR-142-5p. Cell Death Discov. 2021;7:309. doi: https://doi.org/10.1038/s41420-021-00694-8
184. Guan H, Xu H, Chen J, Wu W, Chen D, Chen Y, et al. Circ_0001721 enhances doxorubicin resistance and promotes tumorigenesis in osteosarcoma through miR-758/TCF4 axis. Cancer Cell Int. 2021;21:336. doi: https://doi.org/10.1186/s12935-021-02016-5185. Chen J, Liu G, Wu Y, Ma J, Wu H, Xie Z, et al. CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling. Mol Cancer. 2019;18:150. doi: https://doi.org/10.1186/s12943-019-1076-1
186. Wei W, Ji L, Duan W, Zhu J. CircSAMD4A contributes to cell doxorubicin resistance in osteosarcoma by regulating the miR-218-5p/KLF8 axis. Open Life Sci. 2020;15:848–59. doi: https://doi.org/10.1515/biol-2020-0079
187. Yanbin Z, Jing Z. CircSAMD4A accelerates cell proliferation of osteosarcoma by sponging miR-1244 and regulating MDM2 mRNA expression. Biochem Biophys Res Commun. 2019;516:102–11. doi: https://doi.org/10.1016/j.bbrc.2019.05.182
188. Ji Y, Liu J, Zhu W, Ji J. circ_0002060 enhances doxorubicin resistance in osteosarcoma by regulating the miR-198/ABCB1 axis. Cancer Biother Radiopharm. 2020:cbr.2020.4240. doi: https://doi.org/10.1089/cbr.2020.4240
189. Huang Y, Xie J, Li E. Comprehensive circular RNA profiling reveals circ_0002060 as a potential diagnostic biomarkers for osteoporosis. J Cell Biochem. 2019;120:15688–94. doi: https://doi.org/10.1002/jcb.28838
190. Xie C, Liang G, Xu Y, Lin E. Circular RNA hsa_circ_0003496 contributes to tumorigenesis and chemoresistance in osteosarcoma through targeting (microRNA) miR-370/Krüppel-like factor 12 axis. Cancer Manag Res. 2020;12:8229–40. doi: https://doi.org/10.2147/CMAR.S253969
191. Lin Z, Xie X, Lu S, Liu T. Noncoding RNAs in osteosarcoma: implications for drug resistance. Cancer Lett. 2021;504:91–103. doi: https://doi.org/10.1016/j.canlet.2021.02.007
192. Zhang Z, Zhou Q, Luo F, Zhou R, Xu J, Xiao J, et al. Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis. Hum Cell. 2021;34:1558–68. doi: https://doi.org/10.1007/s13577-021-00564-6
193. Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang Z, et al. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem. 2019;120:9656–66. doi: https://doi.org/10.1002/jcb.28244
194. Zhang J, Ma X, Zhou R, Zhou Y. TRPS1 and YAP1 regulate cell proliferation and drug resistance of osteosarcoma via competitively binding to the target of circTADA2A—miR-129-5p. Onco Targets Ther. 2020;13:12397–407. doi: https://doi.org/10.2147/OTT.S276953
195. Wu Y, Xie Z, Chen J, Chen J, Ni W, Ma Y, et al. Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. Mol Cancer. 2019;18:73. doi: https://doi.org/10.1186/s12943-019-1007-1
196. Pan Y, Lin Y, Mi C. Cisplatin-resistant osteosarcoma cell-derived exosomes confer cisplatin resistance to recipient cells in an exosomal circ_103801-dependent manner. Cell Biol Int. 2021;45:858–68. doi: https://doi.org/10.1002/cbin.11532
197. Soghli Negin, Qujeq D, Yousefi T, Soghli Negar. The regulatory functions of circular RNAs in osteosarcoma. Genomics. 2020;112:2845–56. doi: https://doi.org/10.1016/j.ygeno.2020.03.024
198. Eaton BR, Schwarz R, Vatner R, Yeh B, Claude L, Indelicato DJ, et al. Osteosarcoma. Pediatr Blood Cancer. 2021;68. https://doi.org/10.1002/pbc.28352
199. Dai S, Mo Y, Wang Y, Xiang B, Liao Q, Zhou M, et al. Chronic stress promotes cancer development. Front Oncol. 2020;10:1492. doi: https://doi.org/10.3389/fonc.2020.01492200. Eckerling A, Ricon-Becker I, Sorski L, Sandbank E, Ben-Eliyahu S. Stress and cancer: mechanisms, significance and future directions. Nat Rev Cancer. 2021;21:767–85. doi: https://doi.org/10.1038/s41568-021-00395-5
201. Prater S, McKeon B. Osteosarcoma [Updated 2022 M 29]. Treasure Island, FL: StatPearls Publ; 2022 [cited 2023 Jan 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549868/
202. Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, et al. Molecular biology of osteosarcoma. Cancers (Basel). 2020;12:2130. doi: https://doi.org/10.3390/cancers12082130
203. Brady SW, Ma X, Bahrami A, Satas G, Wu G, Newman S, et al. The clonal evolution of metastatic osteosarcoma as shaped by cisplatin treatment. Mol Cancer Res. 2019;17:895–906. doi: https://doi.org/10.1158/1541-7786.MCR-18-0620
204. Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6:362. doi: https://doi.org/10.1038/s41392-021-00670-9
205. Bleve A, Consonni FM, Porta C, Garlatti V, Sica A. Evolution and targeting of myeloid suppressor cells in cancer: a translational perspective. Cancers (Basel). 2022;14:510. doi: https://doi.org/10.3390/cancers14030510
206. Deng C, Xu Y, Fu J, Zhu X, Chen H, Xu H, et al. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. Cancer Sci. 2020;111:1899–909. doi: https://doi.org/10.1111/cas.14398
207. Uehara T, Eikawa S, Nishida M, Kunisada Y, Yoshida A, Fujiwara T, et al. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects. Int Immunol. 2019;31:187–98. doi: https://doi.org/10.1093/intimm/dxy079
208. Wright EM. SGLT2 and cancer. Pflügers Arch Eur J Physiol. 2020;472:1407–14. doi: https://doi.org/10.1007/s00424-020-02448-4
209. Barbosa AM, Martel F. Targeting glucose transporters for breast cancer therapy: the effect of natural and synthetic compounds. Cancers (Basel). 2020;12:154. doi: https://doi.org/10.3390/cancers12010154
210. Wu W, Zhang Z, Jing D, Huang X, Ren D, Shao Z, et al. SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma. Cell Death Dis. 2022;13:523. doi: https://doi.org/10.1038/s41419-022-04980-w
0 Absract views 3 PDF Downloads 3 Total views
By author names
By article title